Susquehanna International Group’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-15,400
| Closed | -$446K | – | 13759 |
|
|
2025
Q4 | $446K | Buy |
+15,400
| New | +$292K | ﹤0.01% | 9072 |
|
|
2025
Q1 | – | Sell |
-1,252
| Closed | -$44.8K | – | 13093 |
|
|
2024
Q4 | $44.8K | Sell |
1,252
-248
| -17% | -$12.8K | ﹤0.01% | 11724 |
|
|
2024
Q3 | $70.9K | Sell |
1,500
-432
| -22% | -$19.1K | ﹤0.01% | 11232 |
|
|
2024
Q2 | $97.1K | Buy |
1,932
+36
| +2% | +$2.6K | ﹤0.01% | 11046 |
|
|
2024
Q1 | $212K | Buy |
1,896
+40
| +2% | +$3.98K | ﹤0.01% | 10477 |
|
|
2023
Q4 | $108K | Sell |
1,856
-3,484
| -65% | -$140K | ﹤0.01% | 11266 |
|
|
2023
Q3 | $170K | Sell |
5,340
-25,460
| -83% | -$1.21M | ﹤0.01% | 10420 |
|
|
2023
Q2 | $2.53M | Buy |
30,800
+24,816
| +415% | +$3.63M | ﹤0.01% | 4670 |
|
|
2023
Q1 | $615K | Buy |
+5,984
| New | +$840K | ﹤0.01% | 8065 |
|
|
2021
Q4 | – | Sell |
-960
| Closed | -$226K | – | 13613 |
|
|
2021
Q3 | $226K | Buy |
+960
| New | +$280K | ﹤0.01% | 11214 |
|
|
2021
Q2 | – | Sell |
-5,136
| Closed | -$2.08M | – | 13002 |
|
|
2021
Q1 | $2.08M | Buy |
5,136
+4,320
| +529% | +$2.1M | ﹤0.01% | 5832 |
|
|
2020
Q4 | $543K | Sell |
816
-396
| -33% | -$220K | ﹤0.01% | 8094 |
|
|
2020
Q3 | $564K | Buy |
1,212
+744
| +159% | +$376K | ﹤0.01% | 7424 |
|
|
2020
Q2 | $274K | Buy |
+468
| New | +$160K | ﹤0.01% | 8505 |
|
Other funds holding MRSN
Susquehanna International Group's MRSN Position: Q3 2025 in Review
Susquehanna International Group sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 17,975 shares — an estimated $133K sold.
Susquehanna International Group first reported a position in MRSN in Q2 2019 and held it in 24 quarters. The position peaked at $2.13M in Q1 2021. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.
- Susquehanna International Group reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
- Susquehanna International Group sold 17,975 Mersana Therapeutics shares in Q3 2025, an estimated $133K.
- Susquehanna International Group first reported a position in Mersana Therapeutics in Q2 2019 and held it in 24 quarters.
- Susquehanna International Group's Mersana Therapeutics position peaked at $2.13M in Q1 2021.
- 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.